Some people who have mesothelioma don’t produce enough of a certain enzyme. The lack of this enzyme is thought to help mesothelioma grow and spread. Researchers in England and in the U.S. recently wrapped up a Phase 2 clinical trial of a drug designed to make up for this enzyme shortage. The results seem encouraging.